Mirin
(Synonyms: (5Z)-2-氨基-5-[(4-羟基苯基)亚甲基]-4(5H)-噻唑酮) 目录号 : GC13491
Mirin是一种Mre11-Rad50-Nbs1(MRN)复合物抑制剂(IC50=12μM),能够抑制Mre11相关的外切酶活性,Mirin可抑制MRN依赖的ATM的激活。通常用于与DNA修复机制相关的癌症的研究。
Cas No.:1198097-97-0
Sample solution is provided at 25 µL, 10mM.
Mirin is an inhibitor of Mre11-Rad50-Nbs1 (MRN) complex (IC50=12μM), which can inhibit the activity of MRE11-related exonuclease, and can inhibit the activation of MRN-dependent ATM[1]. It is commonly used in the study of cancers related to DNA repair mechanisms[1].
Mirin (100µM, 24 hours) significantly enhanced the sensitivity of human papillomavirus (HPV) to N-methylpyrrole-imidazole hairpin polyamide (PA25)[2]. Mirin (50μM, 24h) significantly enhanced DNA double-strand breaks and promoted cell apoptosis in esophageal squamous cell carcinoma (ESCC) cells treated with NU7441 and ionizing radiation treatment[3].
Mirin (50mg/kg/day, 9 days, intratumoral injection) efficiently restrains tumor growth in Neuroblastoma mouse model by inducing DNA damage response (DDR) and apoptosis[4]. Mirin (50mg/kg, 72 hours, i.p.) significantly increased tubular damage and serum markers of acute kidney injury (AKI) (creatinine and neutrophil gelatinase-associated lipocalin) in cisplatin-induced nephrotoxic AKI mouse model[5].
References:
[1] Dupré A, Boyer-Chatenet L, Sattler RM, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complex. Nature chemical biology. 2008 Feb;4(2):119-25.
[2] Edwards TG, Vidmar TJ, Koeller K, et al. DNA damage repair genes controlling human papillomavirus (HPV) episome levels under conditions of stability and extreme instability. PloS one. 2013 Oct 2;8(10):e75406.
[3] Wang G, Guo S, Zhang W, et al. A comprehensive analysis of alterations in DNA damage repair pathways reveals a potential way to enhance the radio-sensitivity of esophageal squamous cell cancer. Frontiers in oncology. 2020 Oct 16;10:575711.
[4] Petroni M, Sardina F, Infante P, et al. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell death & disease. 2018 Aug 30;9(9):895.
[5] Hama T, Nagesh PK, Chowdhury P, et al. DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity. JCI insight. 2021 Nov 11;6(22).
Mirin是一种Mre11-Rad50-Nbs1(MRN)复合物抑制剂(IC50=12μM),能够抑制Mre11相关的外切酶活性,Mirin可抑制MRN依赖的ATM的激活[1]。通常用于与DNA修复机制相关的癌症的研究[1]。
Mirin(100µM,24小时)显著增强了人乳头瘤病毒(HPV)对N-甲基吡咯-咪唑发夹聚酰胺(PA25)的敏感性[2]。在NU7441和电离辐射处理的食管鳞状细胞癌细胞(ESCC)中,Mirin(50μM,24小时)显著增强DNA双链的断裂,显著促进细胞凋亡[3]。
Mirin(50 mg/kg/d,9天,瘤内注射)在神经母细胞瘤小鼠模型中通过诱导DNA损伤反应(DDR)和细胞凋亡有效抑制肿瘤生长[4]。在顺铂诱导的肾毒性的急性肾损伤(AKI)小鼠模型中,Mirin(50mg/kg,72小时,腹腔注射)显著增加了肾小管损伤和AKI血清标志物(肌酐和中性粒细胞明胶酶相关脂质运载蛋白)[5]。
Cell experiment [1]: | |
Cell lines | W12E cells |
Preparation Method | W12E cells were pre-treated with 100µM Mirin or 0.1% DMSO for 24h. Media was removed and fresh media containing the indicated doses of N-methylpyrrole-imidazole hairpin polyamide (PA25) or 0.1% DMSO was added, and cells incubated an additional 24h. |
Reaction Conditions | 100µM, 24 hours |
Applications | Mirin significantly sensitized human papillomavirus (HPV) episomes to PA25. |
Animal experiment [2]: | |
Animal models | Neuroblastoma mouse model |
Preparation Method | 1. Mirin encapsulation in biocompatible polymeric nanocarriers: |
Dosage form | 50mg/kg/d, 9 days, intratumoral injection |
Applications | Mirin efficiently restrains tumor growth in vivo by inducing DNA damage response (DDR) and apoptosis. |
Cas No. | 1198097-97-0 | SDF | |
别名 | (5Z)-2-氨基-5-[(4-羟基苯基)亚甲基]-4(5H)-噻唑酮 | ||
化学名 | (Z)-5-(4-hydroxybenzylidene)-2-imino-2,5-dihydrothiazol-4-ol | ||
Canonical SMILES | N=C1N=C(O)/C(S1)=C([H])/C2=CC=C(O)C=C2 | ||
分子式 | C10H8N2O2S | 分子量 | 220.25 |
溶解度 | ≥ 9.3mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 4.5403 mL | 22.7015 mL | 45.403 mL |
5 mM | 0.9081 mL | 4.5403 mL | 9.0806 mL |
10 mM | 0.454 mL | 2.2701 mL | 4.5403 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet